Antiplatelet effect of amlodipine A possible mechanism through a nitric oxide-mediated process

Biochemical Pharmacology

Volumn 58, Issue 10, 1999, Pages 1657-1663

  Chou, Tz Chong ^a   Li, Chi Yuan ^a   Yen, Mao Hsiung ^a   Ding, Yu An ^b  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b Veterans General HospitaL Taipei ^*  (Taiwan)

Author keywords

Amlodipine; Guanosine 3',5' cyclic monophosphate; Nitric oxide; Platelet aggregation; Thromboxane B2

Indexed keywords

AMLODIPINE; CYCLIC AMP; CYCLIC GMP; NITRIC OXIDE; THROMBOXANE B2;

ANIMAL CELL; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DRUG EFFECT; NONHUMAN; PRIORITY JOURNAL; RABBIT; THROMBOCYTE AGGREGATION;

AMLODIPINE; ANIMALS; BLOOD PLATELETS; CYCLIC AMP; CYCLIC GMP; DRUG INTERACTIONS; ENZYME INHIBITORS; METHEMOGLOBIN; NG-NITROARGININE METHYL ESTER; NITRATES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RABBITS; THROMBOXANE B2;

EID: 0032884270     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00235-X     Document Type: Article

References (39)

1. Fuster V., Badimon L., Badimon J.J., Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 326:1991;310-318.
2. Ross R. The pathogenesis of atherosclerosis A perspective for the 1990's . Nature. 362:1990;801-809.
3. Mustard J.F. The Gordon Wilson lecture Function of platelets and their role in thrombosis . Trans Am Clin Climatol Assoc. 87:1976;104-127.
4. Packham M.A., Mustard J.F. The role of platelets in the development and complications of atherosclerosis. Semin Hematol. 23:1986;8-26.
5. Kerson L.A., Olmos-Lau N. Review of ischemic cerebrovascular disease Pathophysiology, clinical symptomatology, and their implications for therapy . Cardiovasc Rev Rep. 5:1984;227-239.
6. Kroll M., Schager A. Biochemical mechanisms of platelet activation. Blood. 74:1989;1185-1195.
7. Massini P., Luscher E. On the significance of the influx of calcium ions into stimulated human blood platelets. Biochim Biophys Acta. 21:1981;523-528.
8. Packer M., O'Connor C.M., Ghali J.K., Pressler M.L., Carson P.E., Belkin R.N., Miller A.B., Neuberg G.W., Frid D., Wertheimer J.H., Cropp A.B., DeMets D.L. for the Prospective Randomized Amlodipine Survival Evaluation Study Group, Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med. 335:1996;1107-1114.
9. Folts JD, Inhibition of platelet activity in vivo by amlodipine alone and combined with aspirin. Int J Cardiol 62: S111-S117, 1997.
10. Hernandez R, Carvajal AR and Armas-de-Hernandez MJ, Amlodipine in hypertension: Its effects on platelet aggregation and dynamic exercise. J Cardiovasc Pharmacol 17: S25-S27, 1991.
11. Pales J., Palacios-Araus L., Lopez A., Gaul A. Effect of dihydropyridines and inorganic calcium blockers on aggregation and on intracellular free calcium in platelets. Biochim Biophys Acta. 1064:1991;169-174.
12. Wallen N.H., Held C., Rehnqvist N., Hjemdahl P. Platelet aggregability in vivo is attenuated by verapamil but not by metoprolol in patients with stable angina pectoris. Am J Cardiol. 75:1995;1-6.
13. 2+ channel antagonists. Trends Pharmacol Sci. 13:1992;256-262.
14. Doyle V.M., Ruegg U.T. Lack of evidence for voltage dependent calcium channels on platelets. Biochem Biophys Res Commun. 127:1985;161-167.
15. Mollace V., Salvemini D., Anggard E., Vane J. Studies on the importance of the proposed release of nitric oxide from platelets. Thromb Res. 64:1991;533-542.
16. Mellion B.T., Ignarro L.J., Ohlstein E.H., Pontecorvo E.G., Hyman A.L., Kadowitz P.J. Evidence for the inhibitory role of adenosine 3′,5′-monophosphate in ADP-induced human aggregation in the presence of nitric oxide and related vasodilators. Blood. 57:1981;946-955.
17. Radomski M.W., Palmer R.M.J., Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci USA. 87:1990;5193-5197.
18. Zhang X., Hintze T.H. Amlodipine releases nitric oxide from canine coronary microvessels An unexpected mechanism of action of a calcium channel-blocking agent . Circulation. 97:1998;576-580.
19. Gunther J., Dhein S., Rosen R., Klaus W., Fricke U. Nitric oxide (EDRF) enhances the vasorelaxing effect of nitrendipine in various isolated arteries. Basic Res Cardiol. 87:1992;452-460.
20. Vilaine J.P., Biondi M.L., Villeneuve N., Feletou M., Peglion J.L., Vanhoutte P.M. The calcium channel antagonist S 11568 causes endothelium-dependent relaxation in canine arteries. Eur J Pharmacol. 197:1991;41-48.
21. Berkels R., Klaus W., Boller M., Rosen R. The calcium modulator nifedipine exerts its antiaggregatory property via a nitric oxide mediated process. Thromb Haemost. 72:1994;309-312.
22. Chou T.-C., Hsu l-Y, Yen M.-H., Ding Y.-A. The inhibitory effect of 2-thienyl 2′-hydroxyphenyl ketone (C85) on platelet thromboxane formation. Thromb Res. 84:1996;83-95.
23. Zhou Q., Hellermann G.R., Solomonson L.P. Nitric oxide release from resting human platelets. Thromb Res. 77:1995;87-96.
24. Chou T.-C., Yen M.-H., Li C.-Y., Ding Y.-A. Alterations of nitric oxide synthase expression with aging and hypertension in rats. Hypertension. 31:1998;643-648.
25. Radomski M.W., Moncada S. The biological and pharmacological role of nitric oxide in platelet function. Adv Exp Med Biol. 344:1993;251-264.
26. Takahara K.K., Kuroiwa A., Matsushima T. Effects of nifedipine on platelet function. Am Heart J. 109:1985;4-8.
27. Malinski T., Radomski M.W., Taha Z., Moncada S. Direct electrochemical measurement of nitric oxide released from human platelets. Biochem Biophys Res Commun. 194:1993;960-965.
28. Nguyen BL, Saitoh M and Ware JA, Interaction of nitric oxide and cGMP with signal transduction in activated platelets. Am J Physiol 261: H1043-H1052, 1991.
29. Hawkins D.J., Meyrick B.O., Murray J.J. Activation of guanylate cyclase and inhibition of platelet aggregation by endothelium-derived relaxing factor released from cultured cells. Biochim Biophys Acta. 969:1988;289-296.
30. Nakashima S., Tohmatsu T., Hattori H., Okano Y.A., Nozawa Y. Inhibitory action of cyclic GMP on secretion, polyphosphoinositide hydrolysis and calcium mobilization in thrombin-stimulated human platelets. Biochem Biophys Res Commun. 135:1986;1099-1104.
31. Geiger J, Nolte C and Walter U, Regulation of calcium mobilization and entry in human platelets by endothelium-derived factors. Am J Physiol 267: C236-C244, 1994.
32. Sane D.C., Bielawska A., Greenberg C.S., Hannun Y.A. Cyclic GMP analogs inhibit gamma thrombin-induced arachidonic acid release in human platelets. Biochem Biophys Res Commun. 165:1989;708-714.
33. Armstrong R.A., Jones R.L., Wilson N.H. Ligand binding to thromboxane receptors on human platelets Correlation with biological activity . Br J Pharmacol. 79:1983;953-964.
34. 2+-dependent arachidonic acid liberation in collagen-stimulated rabbit platelets. Biochem Pharmacol. 38:1989;1841-1847.
35. 2 activity specific for phosphatidic acid. A possible mechanism for the production of arachidonic acid in platelets. J Biol Chem. 256:1981;5399-5403.
36. Hishikawa K., Luscher T. Felodipine inhibits free-radical production by cytokines and glucose in human smooth muscle cells. Hypertension. 32:1998;1011-1015.
37. Mak I.T., Weglicki W.B. Antioxidant activity of calcium channel blocking drugs. Methods Enzymol. 234:1994;620-630.
38. Shook L.A., Pauly T.H., Marple S.L., Horstman S.J., Tai H.-H., Bowdy B.D., Gillespie M.N. Group B streptococcus promotes oxygen radical-dependent thromboxane accumulation in young piglets. Pediatr Res. 27:1990;349-352.
39. Salvemini D., Radziszewski W., Mollace V., Moore A., Willoughby D., Vane J. Diphenylene iodonium, an inhibitor of free radical formation, inhibits platelet aggregation. Eur J Pharmacol. 199:1991;15-18.